soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Oral Semaglutide Cuts Cardiovascular Risk

Our experienced team specializes in effective weight management, combining GLP medical weight loss treatments with additional wellness and vitamin injections tailored to your needs

We offer flexible payment plans

In second to minutes, a life can be saved

The 24% figure from retatrutide Phase 2, over a shorter timeframe, is meaningfully ahead of both

Alcohol use, dehydration, and very low food intake can complicate treatment

aleniglipron does not T2D data : Orforglipron has ACHIEVE-3 head-to-head vs oral semaglutide Company backing : Eli Lilly (orforglipron) vs Structure Therapeutics (aleniglipron) Conclusion# The oral GLP-1 small molecule space is developing into a two-horse race between aleniglipron and orforglipron